Quest Diagnostics price target raised to $150 from $145 at Truist

Truist raised the firm’s price target on Quest Diagnostics to $150 from $145 and keeps a Hold rating on the shares after hosting management meetings. The discussions focused on the company’s strong base business trends, areas of growth opportunity, and ongoing cost/efficiency initiatives, the analyst tells investors in a research note. While labor remains a challenge for Quest Diagnostics, the company’s core growth trends are attractive and its M&A and partnership opportunities remain brisk, the firm added.